Zobrazeno 1 - 10
of 271
pro vyhledávání: '"Cynthia Levy"'
Autor:
Robyn von Maltzahn, Marlyn J. Mayo, Helen T. Smith, April Thompson, Sugato Das, Andrea Ribeiro de Souza, Edoardo Lisi, Cynthia Levy, Megan M. McLaughlin, David Jones
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 8, Iss 1, Pp 1-10 (2024)
Abstract Background Cholestatic pruritus and fatigue are debilitating conditions associated with primary biliary cholangitis (PBC) and can significantly impact patients’ quality of life. Pruritus in PBC often worsens at night and patients frequentl
Externí odkaz:
https://doaj.org/article/4d1af5d6eaee470a8aa825e7746d9486
Autor:
Surain B. Roberts, Woo Jin Choi, Lawrence Worobetz, Catherine Vincent, Jennifer A. Flemming, Angela Cheung, Karim Qumosani, Mark Swain, Dusanka Grbic, Hin Hin Ko, Kevork M. Peltekian, Lusine Abrahamyan, Monika Saini, Kattleya Tirona, Bishoi Aziz, Ellina Lytvyak, Pietro Invernizzi, Cyriel Y. Ponsioen, Tony Bruns, Nora Cazzagon, Keith Lindor, George N. Dalekos, Nikolaos K. Gatselis, Xavier Verhelst, Annarosa Floreani, Christophe Corpechot, Marlyn J. Mayo, Cynthia Levy, Maria-Carlota Londoño, Pier M. Battezzati, Albert Pares, Frederik Nevens, Adriaan van der Meer, Kris V. Kowdley, Palak J. Trivedi, Ana Lleo, Douglas Thorburn, Marco Carbone, Nazia Selzner, Aliya F. Gulamhusein, Harry LA. Janssen, Aldo J. Montano-Loza, Andrew L. Mason, Gideon M. Hirschfield, Bettina E. Hansen
Publikováno v:
JHEP Reports, Vol 6, Iss 10, Pp 101168- (2024)
Background & Aims: Biochemical response to ursodeoxycholic acid (UDCA) therapy is associated with good prognosis in people living with primary biliary cholangitis (PBC). Biochemical response is typically assessed early in disease and it is not known
Externí odkaz:
https://doaj.org/article/8d1c44ac78ae4a3ebc2eca8571c39ace
Autor:
Martine Walmsley, Vipul Jairath, Christoph Schramm, Michael Trauner, Christopher Ma, Gideon Hirschfield, Palak J Trivedi, Nasir Hussain, Olalekan Lee Aiyegbusi, Mette Vesterhus, Kris Kowdley, Cyriel Ponsioen, Annika Bergquist, Paula Hanford, Cynthia Levy, David Assis, Christopher Bowlus
Publikováno v:
BMJ Open, Vol 14, Iss 6 (2024)
Background Primary sclerosing cholangitis (PSC) is a progressive immune-mediated liver disease, for which no medical therapy has been shown to slow disease progression. However, the horizon for new therapies is encouraging, with several innovative cl
Externí odkaz:
https://doaj.org/article/a353f7675b1349aaac1af77e8dce4c39
Autor:
Michael Trauner, Chuhan Chung, Kate Sterling, Xiangyu Liu, Xiaomin Lu, Jun Xu, Clare Tempany-Afdhal, Zachary D. Goodman, Martti Färkkilä, Atsushi Tanaka, Palak Trivedi, Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, Robert P. Myers
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Primary sclerosing cholangitis (PSC) is a chronic progressive liver disease leading to biliary fibrosis and cirrhosis. Cilofexor is a nonsteroidal farnesoid X receptor agonist that demonstrated significant improvements in liver bi
Externí odkaz:
https://doaj.org/article/f6de658e3d0a4a3c807ec2a098703885
Autor:
Cynthia Levy, Karl E. Anderson, Manisha Balwani, Herbert L. Bonkovsky, Amy Dickey, Siobán Keel, Brendan Mcguire, Roy Smith, Manish Thapar, Bruce Wang, William Savage
Publikováno v:
HemaSphere, Vol 7, p e904346e (2023)
Externí odkaz:
https://doaj.org/article/f2e13231cb1848a0a6e7f2207e468328
Publikováno v:
European Medical Journal Hepatology (2023)
Cholestatic liver diseases include primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and progressive familial intrahepatic cholestasis (PFIC). In all of these conditions, cholestatic itch is a major symptom that can severely an
Externí odkaz:
https://doaj.org/article/f6303c114632435ab1075218a3143385
Autor:
David Jones, Marco Carbone, Pietro Invernizzi, Nicola Little, Frederik Nevens, Mark G. Swain, Philippe Wiesel, Cynthia Levy
Publikováno v:
Hepatology Communications, Vol 7, Iss 3, Pp e0057-e0057 (2023)
Background:. There is a real unmet need for primary biliary cholangitis (PBC) treatments that can improve quality of life impacting symptoms. In this post hoc analysis, we evaluated potential effects of the NADP oxidase 1/4 inhibitor, setanaxib, on p
Externí odkaz:
https://doaj.org/article/9ce47b2b75e34bd29cbbba9a3594d8eb
Autor:
Christoph Schramm, Heiner Wedemeyer, Andrew Mason, Gideon M. Hirschfield, Cynthia Levy, Kris V. Kowdley, Piotr Milkiewicz, Ewa Janczewska, Elena Sergeevna Malova, Johanne Sanni, Phillip Koo, Jin Chen, Subhajit Choudhury, Lloyd B. Klickstein, Michael K. Badman, David Jones
Publikováno v:
JHEP Reports, Vol 4, Iss 11, Pp 100544- (2022)
Background & Aims: The safety, tolerability, and efficacy of the non-bile acid farnesoid X receptor agonist tropifexor were evaluated in a phase II, double-blind, placebo-controlled study as potential second-line therapy for patients with primary bil
Externí odkaz:
https://doaj.org/article/3923e32517ec458db31731c6b79c2204
Autor:
Binu V. John, Kaley Schwartz, Cynthia Levy, Bassam Dahman, Yangyang Deng, Paul Martin, Tamar H. Taddei, David E. Kaplan
Publikováno v:
Hepatology Communications, Vol 5, Iss 8, Pp 1426-1436 (2021)
Obeticholic acid (OCA) is approved for the treatment of patients with primary biliary cholangitis (PBC) who are partial responders or intolerant to ursodeoxycholic acid. Reports of serious liver injury have raised concerns about its safety in cirrhos
Externí odkaz:
https://doaj.org/article/e52c318199354e8384535aedfb7cbf35
Publikováno v:
Frontiers in Genetics, Vol 13 (2022)
Introduction: 5-Aminolevulinic acid dehydratase (ALAD) porphyria (ADP) is an autosomal recessive disease characterized by a profound deficiency in ALAD, the second enzyme in the heme biosynthetic pathway, and acute neurovisceral attacks with abdomina
Externí odkaz:
https://doaj.org/article/383cb065b29a42e991918ffd65cda0aa